Expertise in drug development

The development of biologics demands precision, robustness and a deep understanding of how structure, process and formulation interact. RISE provides integrated support across the entire development chain – from early drug substance characterisation to formulation, analytical method development and…

Drug development is fraught with risk: unexpected toxicity, unstable compounds, and poorly characterized molecules can delay projects or halt them entirely. RISE provides integrated analytics for small molecules and biologics, reducing risk and accelerating preclinical readiness.

Unexpected toxicity, insufficient exposure, or inadequate risk assessment are common reasons why drug development projects are delayed or halted. RISE helps you identify risks early, ensuring your project can proceed safely and efficiently.

Developing small-molecule drug substances requires robust chemistry, scalable processes, and early regulatory alignment. Wrong decisions at this stage often lead to late redesigns, increased costs, and delays before clinical trials.

Developing small molecule drug products requires precise control of physicochemical properties, formulation stability, bioavailability, and safety. Early-stage planning, scalable processes and regulatorily compliant workflows are essential for successful clinical progression.

Early-stage drug development comes with critical challenges: candidate selection, manufacturability, stability, and regulatory alignment all influence the success of your program. Making informed, data-driven decisions at this stage reduces risk, accelerates timelines, and improves the likelihood o…